P43 Cost-Effectiveness of Talquetamab-tgvs Vs Idecabtagene Vicleucel for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.069
https://www.valueinhealthjournal.com/article/S1098-3015(24)00184-0/fulltext
Title :
P43 Cost-Effectiveness of Talquetamab-tgvs Vs Idecabtagene Vicleucel for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00184-0&doi=10.1016/j.jval.2024.03.069
First page :
Section Title :
Open access? :
No
Section Order :
10013